European Commission Directorate-General for International Partnerships (EuropeAid HQ)

Fighting Large-Scale Untreated Infectious Diseases with Innovative Treatments: FLUIDITY

Last update: Mar 28, 2023 Last update: 28 Mar, 2023

Details

Locations: France
Start Date: Jan 1, 2023
End Date: Dec 31, 2024
Contract value: EUR 4,582,237
Sectors: Health, Science & Innovation Health, Science & Innovation
Categories: Grants
Date posted: Mar 28, 2023

Associated funding

Associated experts

Description

Programme(s): HORIZON.3.1 - The European Innovation Council (EIC)

Topic(s): HORIZON-EIC-2022-ACCELERATOROPEN-01 - EIC Accelerator Open

Call for proposal: HORIZON-EIC-2022-ACCELERATOR-01

Funding Scheme: EIC-ACC - EIC-ACC

Grant agreement ID: 190144923

Objective:
Founded in 2020, Meletios is developing innovative antiviral strategies to treat existing and emerging acute viral infections. Among those, our lead program, presented at the EIC Accelerator, is an oral Host-Directed Agent targeting cell mechanisms hijacked by viruses. By acting on cell membrane’s fluidity, our antiviral strongly limits cell internalization and intracellular trafficking of viruses. This approach could be effective against broad virus families, conferring our molecule with an advantageous broad-spectrum effect, a key strategy to boost our capacities to ward off outbreaks. Moreover, our agent has immunomodulatory effects enabling to efficiently manage viral diseases by preventing excessive immune system reactions.
We will perform an accelerated development process as our molecule has already proved it safety in humans. COVID-19 will be the first demonstrator of our molecule’s efficacy, before targeting diseases induced by other coronaviruses, influenza, flaviviruses.

 

Want to unlock full information?
Member-only information. Become a member to access projects awards, find the right consortia partners, subcontractors and more.
Learn more about our membership benefits